SLC5A2 and hydrops fetalis: A 2024 meta-analysis by Neuen et al. showed that GLP-1 receptor agonists, whether used alone or in combination with SGLT2 inhibitors, reduce the risk of MACE by ~20-25%, HF hospitalizations, and composite kidney outcomes (≥50% eGFR decline, kidney failure, or death from kidney causes), relative to placebo.